The Future of GLP-1RAs in Obesity Treatment: Expert Perspective
With the recent surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.
The future of glucagon-like peptide-1 (GLP-1) receptor agonists in obesity treatment holds significant promise, though current challenges such as supply shortages, cost, and insurance coverage persist. The long-term success of GLP-1 receptor agonists hinges on a multifaceted approach that incudes lifestyle interventions, medication adherence, and addressing weight bias and stigma, according to Michael Crotty, MD, a general practitioner who specializes in obesity medicine and is co-founder of My Best Weight in Dublin, Ireland. He explains in the short video above.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
